Immuno-oncology of differentiated thyroid cancer
暂无分享,去创建一个
[1] J. French. Immunotherapy for advanced thyroid cancers — rationale, current advances and future strategies , 2020, Nature Reviews Endocrinology.
[2] S. Wen,et al. Immune Microenvironment of Thyroid Cancer , 2020, Journal of Cancer.
[3] Song Wu,et al. Immune Cell Confrontation in the Papillary Thyroid Carcinoma Microenvironment , 2020, Frontiers in Endocrinology.
[4] G. Marone,et al. Immune and Inflammatory Cells in Thyroid Cancer Microenvironment , 2019, International journal of molecular sciences.
[5] A. Antonelli,et al. The Immune Landscape of Thyroid Cancer in the Context of Immune Checkpoint Inhibition , 2019, International journal of molecular sciences.
[6] F. D. De Braud,et al. Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer , 2019, BMC Cancer.
[7] R. Melillo,et al. Recent advances in understanding immune phenotypes of thyroid carcinomas: prognostication and emerging therapies , 2019, F1000Research.
[8] K. Nakano,et al. A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer. , 2019, Future oncology.
[9] K. Jung,et al. Clinicopathological significance of cancer-associated fibroblasts in papillary thyroid carcinoma: a predictive marker of cervical lymph node metastasis , 2018, European Archives of Oto-Rhino-Laryngology.
[10] K. J. Na,et al. Immune landscape of papillary thyroid cancer and immunotherapeutic implications. , 2018, Endocrine-related cancer.
[11] W. Arafat,et al. Novel targeted therapies and immunotherapy for advanced thyroid cancers , 2018, Molecular Cancer.
[12] K. Tamura,et al. Pembrolizumab for advanced papillary or follicular thyroid cancer: preliminary results from the phase 1b KEYNOTE-028 study. , 2016 .
[13] M. Molloy,et al. Proteomics of thyroid tumours provides new insights into their molecular composition and changes associated with malignancy , 2016, Scientific Reports.
[14] Xiangdong Wang,et al. Cancer Moonshot 2020: a new march of clinical and translational medicine , 2016, Clinical and Translational Medicine.
[15] L. Ward. Immune Response in Thyroid Cancer: Widening the Boundaries , 2014, Scientifica.
[16] Ping Zhang,et al. COX-2 Expression and Tumor Angiogenesis in Thyroid Carcinoma Patients among Northeast Chinese Population-Result of a Single-Center Study , 2012, International journal of medical sciences.
[17] Sameer Gupta,et al. Sperm-associated antigen 9: a novel diagnostic marker for thyroid cancer. , 2009, The Journal of clinical endocrinology and metabolism.
[18] P. Surányi,et al. Immunogenetic and immunologic studies of differentiated thyroid cancer , 1989, Cancer.
[19] G. Chand. Immunological Oncogenic Factors in Differentiated Thyroid Cancer , 2020, Open Access Journal of Endocrinology.